Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CFTR modulator concentrations on clinical response in cystic fibrosis.

The European respiratory journal - 1 Jun 2026

Chalamalla Ashritha R, Baker Elizabeth, Ryan Kevin J, Dowell Alexander, Natt Jennifer R, Zemanick Edith T, Konstan Michael W, Mayer-Hamblett Nicole, Acosta Edward P, Guimbellot Jennifer S

Abstract excerpt

RATIONALE: Cystic fibrosis (CF) is caused by variants in the CF transmembrane conductance regulator (CFTR), leading to defective chloride ion transport and multiorgan dysfunction. CFTR modulators substantially improve chloride ion transport and disease severity, but responses vary, which may in part be due to variation in drug concentrations. OBJECTIVES: This study aimed to evaluate modulator concentrations among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Benzodioxoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chlorides

Share to Pyrazoles

Share to Pyrrolidines

Share to Quinolines

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 41713946
DOI: 10.1183/13993003.01594-2025
PMCID: PMC13086501

Genes

CFTR
CYP3A5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CFTR modulator concentrations on clinical response in cystic fibrosis.PMID 41713946Read ↗

Real-world data confirm elexacftor/tezacaftor/ivacaftor modulators halves sweat chloride concentration in eligible people with cystic fibrosis.Semantic proximity Read ↗

Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis.Semantic proximity Read ↗

Precision Medicine Based on CFTR Genotype for People with Cystic FibrosisSemantic proximity Read ↗

Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study.Semantic proximity Read ↗

Contributors to the heterogeneity of response to CFTR modulators.Semantic proximity Read ↗

Genotype-dependent biochemical response to elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis: A 24-month real-world study.Semantic proximity Read ↗

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.Semantic proximity Read ↗

Response to modulator therapy in a cystic fibrosis patient with a single identified CFTR variant not eligible for modulator treatment.Semantic proximity Read ↗

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational StudySemantic proximity Read ↗

Real-world effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis patients with Phe508del -gating and -residual function genotypes.Semantic proximity Read ↗

Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.Semantic proximity Read ↗

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.